CareMiBrain, the Oncovision brain dedicated PET, recently passed all the electromagnetic compatibility trials through an independent certified laboratory, according to the international regulation IEC 60601-1-2 for electro medical devices. The technology is electromagnetically compatible, so it works alongside other medical devices without causing interference.
Electromagnetic compatibility (EMC) testing evaluates the unintentional generation, propagation or reception of electromagnetic energy that can damage equipment or interfere with the way the equipment operates. EMC testing for CareMiBrain took place in a certified anechoic chamber, designed for absorbing reflections of electromagnetic waves, at AT4’s facilities for EMC testing and certification.
EMC certification allows Oncovision to continue development of CareMiBrain as scheduled, beginning with a pilot study beginning in the third quarter of 2017 when a referenced medical center will install CareMiBrain.
CareMiBrain is a Project part of the European Commission’s Horizon 2020 research and innovation program under grant agreement Nº 711323.
Oncovision is a leading provider of innovative medical imaging devices used by surgeons, radiologists, oncologists and nuclear physicians for the diagnosis and treatment of cancer.
Oncovision has offices in Boston, MA (USA) and Valencia, Spain and sells its products in over 30 markets through a combination of direct sales and distributors. Its main investors are CRB Inverbio through its Fund CRB Bio II, and Bullnet Capital.